Is Cencora Stock Underperforming the Dow?

Is Cencora Stock Underperforming the Dow?

Aritra Gangopadhyay

Wed, September 9, 2026 at 3:19 PM GMT+3 2 min read

• COR -0.73%
• ^DJI -0.60%

Conshohocken, Pennsylvania-based Cencora, Inc. (COR) sources and distributes pharmaceutical products in the United States and internationally. Valued at a market cap of $61.6 billion, the company distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, and more.

Companies with a market cap of $10 billion or more are typically referred to as "large-cap stocks." COR fits perfectly into that category, with its market cap exceeding this threshold and reflecting its substantial size and influence in the medical distribution industry.

More News from Barchart

Despite its strength, COR stock is down 14% from its 52-week high of $377.54, touched on Nov. 25, 2025. Moreover, COR has risen 18.5% over the past three months and has outperformed the Dow Jones Industrial Average ($DOWI), which has grown 3.9% during the same period.

Zooming out a little further, the scenario changes. Over the past 52 weeks, COR has surged 9%, lagging behind DOWI's 16% gain.

COR has been trading above its 200-day moving average since the end of August and also above its 50-day moving average since July.

COR's short-term outperformance and bullish momentum could be traced back to its Q3 2026 earnings. The company's revenue for the quarter amounted to $84.8 billion and missed the Street's estimates. However, its adjusted EPS came in at $4.48 and topped Wall Street's forecasts. Cencora expects full-year earnings in the range of $17.75 to $17.95 per share. The company's shares rose 3.6% following the release.

When stacked against its peer, Cardinal Health, Inc. (CAH), COR has underperformed. Over the past year, CAH stock has grown 60%.

However, sentiment on COR remains highly optimistic. Among the 15 analysts covering the stock, the consensus rating is a "Strong Buy." Its mean price target of $366.50 suggests 12.9% upside from current levels.

On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com